THE ESSENTIALS IN 30 SECONDS

  • MedInTech raised 33.8 billion won in a Series C co-led by Atinum Investment and KB Investment, bringing cumulative funding to about 62.2 billion won.
  • Its INTION S endoscope replaces manual wire control with motors and adds AI-assisted steering; a 178-patient study found it non-inferior to standard scopes.
  • The company plans to develop surgical robots and seek regulatory approvals, and says it will add more investors before closing the round this year.

South Korean medical robotics startup MedInTech announced on November 17 that it has raised 33.8 billion won (roughly US$25 million) in a Series C round. Atinum Investment, an existing backer, and KB Investment, a new one, led the round jointly. Earlier investors Smilegate Investment, SL Investment, ICF (Nextrans) and Woosin Venture Investment returned, and K2 Investment Partners joined for the first time.

According to Korean outlets Venturesquare and AI Times, the company's cumulative funding now stands at about 62.2 billion won, following an 8 billion won Series A in 2022 and a 20 billion won Series B in 2024. MedInTech says it intends to bring in further investment before the end of the year and then close the Series C, so the final size of the round may grow.

A motorised endoscope with AI steering

Founded in 2020, MedInTech builds equipment for gastrointestinal endoscopy, a procedure in which doctors still largely steer the scope by hand by pulling control wires. Its INTION S robotic endoscope replaces that mechanism with motor-driven control and adds AI-based autonomous steering that helps with direction and with tracking lesions. A companion software product, INTION DEEPEYE, is designed to detect and classify abnormal areas in upper GI and colonoscopy images.

The company points to a study at Seoul National University Hospital involving 178 adults, published in Scientific Reports, which found the robotic scope non-inferior to conventional mechanical endoscopes on key handling measures while reducing physicians' physical fatigue and workload. A multi-centre trial has followed. Through a distribution agreement with DK Healthcare, INTION S is supplied to the National Fire Service Hospital and Ajou University Hospital, and the company reports initial sales in Thailand, the Philippines and Mongolia.

From diagnosis to surgery

MedInTech says the new money will go towards a broader endoscope lineup and towards developing surgical robots, both for procedures inside the body and external ones, built on its motor-drive and precision-control technology. Planned spending covers R&D hiring, prototypes, domestic and international regulatory approvals and mass-production capacity. CEO Lee Chi-won described the goal as a medical robot platform running from diagnosis to treatment and surgery. Separately, it was selected in April for a 22.8 billion won government R&D project on autonomous steering and miniature instruments.

What remains uncertain

The surgical robots are at the development stage, and no timeline for clinical trials or approvals has been disclosed. Moving from diagnostic endoscopes to surgical systems means a heavier burden of clinical evidence and regulatory review, and the market already includes large incumbents such as Intuitive Surgical and Medtronic. Dollar conversions vary between reports; the won amount is the figure the company announced.